ProKidney Corp

We are a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient’s own cells isolated from the patient intended for treatment.
Our approach seeks to redefine the treatment of chronic kidney disease (“CKD”), shifting the emphasis away from management of kidney failure, to the restoration or improvement of kidney function to stop or delay progression of CKD. Our lead product candidate, REACT™, is designed to stabilize or improve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes selected renal cells (SRCs) prepared from a patient’s own, autologous, renal cells.

Our investigational process to restore kidney function begins when a small biopsy of the diseased kidney is sent to our laboratory. We identify the patient’s healthy cells and formulate them into a personalized cell therapy product that is then re-injected into the damaged kidney to assess whether the investigational cell therapy can repair damaged tissue and / or restore kidney function.

To date, clinical studies suggest that treatment with REACT in patients with type 2 diabetes and CKD may positively impact renal function by stabilizing eGFR or attenuating the rate of eGFR decline. Preclinical studies indicate that REACT may migrate throughout the kidney, resulting in an improvement in renal function and histologic structure, including decreased interstitial fibrosis and inflammation.

REACT, an autologous homologous cell admixture, is made from expanded autologous SRCs, obtained from each individual subject’s kidney biopsy. To manufacture REACT, biopsy tissue from each enrolled subject will be sent to ProKidney, in whose facilities renal cells will be expanded and SRCs selected. SRCs are then formulated into the cryopreserved or gelatin-based hydrogel product at a concentration of 100 x 106 cells/mL, and shipped to the clinical site.